Adam's Take By Adam Feuerstein Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts
Biotech By Adam Feuerstein and Matthew Herper STAT’s guide to the most important, beneficial drugs approved in the past decade
Adam's Take By Adam Feuerstein Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list
Adam's Take By Adam Feuerstein And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!
Adam's Take By Adam Feuerstein Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!
Adam's Take By Adam Feuerstein The good, the bad, and the really, really ugly behind Sarepta’s drug approval
Adam's Take By Adam Feuerstein Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Adam's Take By Adam Feuerstein Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
Adam's Take By Adam Feuerstein A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling
Adam's Take By Adam Feuerstein The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results
Adam's Take By Adam Feuerstein Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share
Adam's Take By Adam Feuerstein Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person
Adam's Take By Adam Feuerstein FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Adam's Take By Adam Feuerstein This troubled biotech needed cash, so it turned to a predatory lender: its own CEO
Adam's Take By Adam Feuerstein Sarepta’s bad week raised questions about its gene therapy program. Here are some answers
Adam's Take By Adam Feuerstein Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future
Adam's Take By Adam Feuerstein With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug
Adam's Take By Adam Feuerstein The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies
Adam's Take By Adam Feuerstein Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk
Adam's Take By Adam Feuerstein Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why
Adam's Take By Adam Feuerstein Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics
Biotech By Adam Feuerstein Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup
Adam's Take By Adam Feuerstein Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said
Adam's Take By Adam Feuerstein Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?
Adam's Take By Adam Feuerstein Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales
Adam's Take By Adam Feuerstein Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes
Adam's Take By Adam Feuerstein Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma
Adam's Take By Adam Feuerstein What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease
